Recent Stages I-II Gastric Cancer News

Proton Beam Therapy May Improve Outcomes for Esophageal Cancer (January 23, 2017)

Currently a standard treatment for several gastrointestinal cancers (GI) combines the use of chemotherapy and radiation followed by surgical resection. Radiation may be part of the treatment strategy for... Continue Reading

FDA Clears Marketing Approval for Device to Reduce Hair Loss during Chemotherapy (January 4, 2016)

The United States Food and Drug Administration (FDA) cleared for marketing the first cooling cap to reduce hair loss due to chemotherapy. The cooling cap (Dignitana DigniCap Cooling System) is to be used... Continue Reading

Reolysin® Receives FDA Designation for Gastric Cancer (May 14, 2015)

The U.S. Food and Drug Administration (FDA) has granted an Orphan Drug Designation (ODD) to Reolysin®, an injectable cancer-killing virus, for the treatment of gastric cancer. Oncolytics Biotech® Inc.... Continue Reading

U.S. FDA Issues Warning about Certain Type of Endoscope (February 20, 2015)

The U.S. Food and Drug Administration (FDA) has issued a Safety Communication about a certain type of endoscope­—specifically the device used in endoscopic retrograde cholangiopancreatography (ERCP).... Continue Reading

Adjuvant Radiochemotherapy Demonstrates Benefit in Gastric Cancer (September 25, 2012)

Adjuvant radiochemotherapy provides strong and persistent benefit in patients who have undergone curative gastric resection, according to the long-term results of a study published in the Journal of Clinical... Continue Reading

XELOX May Improve Survival in Gastric Cancer (June 24, 2011)

The chemotherapy regimen referred to as XELOX may improve overall survival compared with observation alone in stages II and III gastric (stomach) cancer; however, data are still immature and longer follow-up... Continue Reading

Genetic Variant Associated with Poor Outcome for Gastric Cancer (May 24, 2010)

Patients with gastric cancer who have a certain type of inherited variation in the CD44 gene experience a significantly shorter time to disease recurrence (2.1 years) compared with patients without the... Continue Reading

Adjuvant Chemotherapy Clinical Trial Data from Last 30 Years Evaluated to Determine Benefit in Gastric Cancer (May 15, 2010)

A moderate but statistically significant survival benefit was reported with the addition of chemotherapy to surgery in patients with resectable gastric cancer (gastric cancer that can be surgically ... Continue Reading

Identification of Cellular Enzymes May Predict Prognosis of Gastric Cancer (March 8, 2009)

Identification of Cellular Enzymes May Predict Prognosis of Gastric Cancer An important enzyme known as histone deacetylase may contain useful information about the prognosis of gastric cancer. These findings... Continue Reading

Combination of Chemotherapy and Immunotherapy Shows Promise for Gastric Cancer (March 8, 2009)

Combination of Chemotherapy and Immunotherapy Shows Promise for Gastric Cancer A combination of chemotherapy and immunotherapy (chemoimmunotherapy) may improve overall survival among gastric cancer patients.... Continue Reading

Next Page »